The GLP-1 pill race
For years, GLP-1 therapy meant injections. The first oral option, Novo Nordisk's oral semaglutide, reached weight-loss approval in December 2025 — but as a peptide it needs to be taken fasting, with a small sip of water, and nothing else for a window afterwards. Eli Lilly took a different chemical route with orforglipron: not a peptide at all, but a small molecule that behaves like a conventional oral drug.
That distinction is the whole story. A small molecule survives digestion, so orforglipron can be swallowed at any time of day, with or without food or water — the first GLP-1 pill without those restrictions. The FDA approved it as Foundayo on 1 April 2026, one of the fastest new-drug approvals in decades.
It is manufactured and marketed by Eli Lilly, the same company behind tirzepatide (Mounjaro / Zepbound), and it slots in as the convenient, needle-free entry point to GLP-1 therapy — albeit with somewhat lower peak weight loss than the strongest injectables.
Why "small molecule" is the headline: Peptide GLP-1 drugs are fragile in the gut, which is why they are injected — or, in oral semaglutide's case, taken under strict conditions. Orforglipron is a non-peptide small molecule, so it is orally stable like an ordinary tablet. That is what unlocks once-daily, anytime, no-restriction dosing — the practical advantage driving its adoption.
A GLP-1 agonist you can swallow
Mechanism of Action
In the ATTAIN obesity programme, the higher doses produced roughly 11% mean weight loss over 72 weeks — meaningful, though generally below the peak figures seen with the strongest injectables like tirzepatide. In type 2 diabetes, a head-to-head trial published in The Lancet showed orforglipron beat oral semaglutide on both blood-sugar control and weight loss.
Interactions matter: orforglipron is affected by CYP3A4, so the maximum dose is capped at 9 mg when taken with a strong CYP3A4 inhibitor, and strong inducers should be avoided. Renal impairment (including ESRD) and mild-to-moderate hepatic impairment did not require dose changes in the label.